Compare OII & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OII | STOK |
|---|---|---|
| Founded | 1964 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.0B |
| IPO Year | 1994 | 2019 |
| Metric | OII | STOK |
|---|---|---|
| Price | $34.00 | $31.17 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 10 |
| Target Price | $31.33 | ★ $36.80 |
| AVG Volume (30 Days) | ★ 1.4M | 690.8K |
| Earning Date | 04-22-2026 | 03-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 142.36 | 92.73 |
| EPS | ★ 3.49 | N/A |
| Revenue | ★ $2,784,156,000.00 | $184,420,000.00 |
| Revenue This Year | $3.48 | N/A |
| Revenue Next Year | $5.62 | $74.28 |
| P/E Ratio | $9.72 | ★ N/A |
| Revenue Growth | 4.62 | ★ 404.50 |
| 52 Week Low | $15.46 | $5.35 |
| 52 Week High | $39.00 | $40.22 |
| Indicator | OII | STOK |
|---|---|---|
| Relative Strength Index (RSI) | 49.65 | 39.74 |
| Support Level | $21.51 | $20.33 |
| Resistance Level | $36.66 | $35.75 |
| Average True Range (ATR) | 1.58 | 2.40 |
| MACD | -0.45 | -0.65 |
| Stochastic Oscillator | 25.11 | 4.24 |
Oceaneering International Inc is a provider of engineered services and products and robotic solutions to the offshore energy, defense, aerospace, manufacturing, and entertainment industries. A majority of its products are produced for the offshore oil and gas market. The company's business segments are Integrity Management and Digital Solutions, Subsea Robotics, Manufactured Products, Offshore Projects Group, and Aerospace and Defense Technologies. Maximum revenue is generated from its Subsea Robotics segment, which provides remotely operated vehicles (ROVs) for drill support and vessel-based services, underwater surveys, tooling, and other activities. Geographically, the company derives its key revenue from the United States, followed by Africa, Norway, Brazil, and other regions.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.